Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025)

Invivyd's (IVVD) quarterly Non-Current Deferred Tax Liability came in at $74.4 million in Q4 2025, down 19.14% on a YoY basis from $92.0 million in Q4 2024, and down 19.14% quarter-over-quarter from $92.0 million in Q4 2024.

Analysis

Invivyd (IVVD) Non-Current Deferred Tax Liability (2023 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $74.4 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 19.14% year-over-year to $74.4 million; the trailing twelve-month figure through Dec 2025 stood at $74.4 million (down 19.14% YoY), and the FY2025 full-year result was $74.4 million, down 19.14% from the prior year.
  • Non-Current Deferred Tax Liability fell to $74.4 million in Q4 2025 per IVVD's latest filing, from $92.0 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $92.0 million in Q4 2024 and bottomed at $74.1 million in Q4 2023.
  • Historically, Non-Current Deferred Tax Liability has averaged $80.1 million across 3 years, with a median of $74.4 million in 2025.
  • The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability advanced 24.07% in 2024, then decreased 19.14% in 2025.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $74.1 million in 2023, then increased by 24.07% to $92.0 million in 2024, then declined by 19.14% to $74.4 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $74.4 million, $92.0 million, and $74.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 74.35 Mn
Dec 31, 2024 91.95 Mn
Dec 31, 2023 74.12 Mn